These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 16354311)

  • 21. [New strategies for NSCLC: is inhibition of tumour vasculature useful].
    Reinmuth N; Steins M; Kreuter M; Thomas M
    Pneumologie; 2010 Jun; 64(6):376-86. PubMed ID: 20229453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
    Gadgeel SM
    Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
    Horsman MR; Siemann DW
    Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
    Taillade L; Alexandre I; Billemont B; Meric JB; Sultan-Amar V; Rixe O
    Bull Cancer; 2009; 96 Suppl 1():S45-55. PubMed ID: 19433373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities].
    Clément-Duchêne C; Godbert B; Martinet Y
    Rev Mal Respir; 2012 Feb; 29(2):161-77. PubMed ID: 22405111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining radiotherapy and angiogenesis inhibitors: clinical trial design.
    Citrin D; Ménard C; Camphausen K
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):15-25. PubMed ID: 16377411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
    Girard N
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.
    Chu BF; Otterson GA
    Clin Lung Cancer; 2016 Nov; 17(6):493-506. PubMed ID: 27381269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the tumor vascular compartment to improve conventional cancer therapy.
    Feron O
    Trends Pharmacol Sci; 2004 Oct; 25(10):536-42. PubMed ID: 15380938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
    Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
    Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic agents.
    Stani SC; Capaccetti B; Bonginelli P; Sarmiento R; De Sio L; Fanelli M; Gasparini G
    Suppl Tumori; 2002; 1(4):S39-43. PubMed ID: 12415816
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review.
    Clément-Duchêne C; Wakelee H
    J Thorac Oncol; 2010 Jan; 5(1):129-39. PubMed ID: 19952799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting angiogenesis in squamous non-small cell lung cancer.
    Piperdi B; Merla A; Perez-Soler R
    Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.